

Neotack[®]

Ranitidine HCl

Neotack[®] is the brand name of Ranitidine. It is a histamine H₂-receptor antagonist. As a result of its H₂-receptor blocking action **Neotack[®]** promotes rapid and effective ulcer healing with sustained pain relief, both day and night by reduction of gastric acid output. After oral administration Ranitidine is rapidly absorbed from the G.I. tract. **Neotack[®]** injection is administered intravenously or intramuscularly. After IM administration the drug is absorbed very rapidly and almost completely from the site of injection. Therapeutic concentration, necessary to inhibit gastric secretion, is maintained for 6-8 hours both after I.V./I.M. Injection.

Ranitidine is widely distributed throughout the body and is 10-19% protein bound. Ranitidine is metabolized in the liver and excreted principally in urine.

COMPOSITION:

Neotack[®] 150 Tablet	: Each film coated tablet contains Ranitidine 150 mg as Ranitidine hydrochloride USP.
Neotack[®] 300 Tablet	: Each film coated tablet contains Ranitidine 300 mg as Ranitidine hydrochloride USP.
Neotack[®] Injection	: Each 2ml ampoule contains 50 mg Ranitidine as Ranitidine hydrochloride USP.
Neotack[®] Syrup	: Each 5ml syrup contains Ranitidine 75 mg as Ranitidine hydrochloride USP.

INDICATION

Peptic ulcer (Duodenal ulcer, Gastric ulcer), Reflux esophagitis, Zollinger-Ellison syndrome, post operative ulcer and other conditions where reduction of gastric secretion and acid output is desirable, such as, the prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients, the prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers and before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson's syndrome), particularly obstetric patients during labour.

DOSAGE AND ADMINISTRATION

Peptic ulcer: 150 mg twice daily with breakfast and at night or 300 mg as a single daily dose at night for 4 weeks. Maintenance therapy: 150 mg at night.

Reflux esophagitis 150 mg twice daily or 300 mg as a single daily dose at night for up to 8 weeks.

Zollinger-Ellison Syndrome: 150mg 3 times daily and this may be increased if necessary to 6g daily in divided doses.

Neotack[®] injection may be given either as a slow (over a period of at least two minutes) intravenous injection of 50 mg, after dilution to a volume of 20 ml per 50 mg dose, which may be repeated every six to eight hours, or as an intermittent intravenous infusion at a rate of 25 mg per hour for two hours; the infusion may be repeated at six to eight hour intervals, or as an intramuscular injection of 50 mg (2 ml) every six to eight hours.

In the prophylaxis of haemorrhage from stress ulceration in seriously ill patients or the prophylaxis of recurrent haemorrhage in patients bleeding from peptic ulceration, parenteral administration may be continued until oral feeding commences.

In the prophylaxis of upper gastrointestinal haemorrhage from stress ulceration in seriously ill patients a priming dose of 50 mg as a slow intravenous injection followed by a continuous intravenous infusion of 0.125-0.250 mg/kg/hour may be preferred.

In patients considered to be at risk of developing aspiration syndrome **Neotack**[®] injection 50 mg may be given intramuscularly or by slow intravenous injection 45 to 60 minutes before induction of general anaesthesia.

Children : The recommended oral dose for the treatment of peptic ulcer in children is 2 mg/kg to 4 mg/kg twice daily to a maximum of 300 mg ranitidine per day. Safety and effectiveness of **Neotack**[®] injection have not been established in case of children.

ADVERSE REACTIONS

Adverse effects of ranitidine are generally infrequent and minor. Headache, malaise, dizziness, constipation, nausea, abdominal pain and rash may occur. Mental confusion and hallucination have occurred in geriatric patients during ranitidine therapy.

PRECAUTION

It should be used with caution in patients with impaired renal function, hepatic dysfunction, pregnancy, lactating mothers and suspected malignancy.

HOW SUPPLIED

Neotack[®] 150 Tablet : Box containing 10x10 tablets in Alu-Alu blister pack.


Neotack[®] 300 Tablet : Box containing 10x10 tablets in Alu-Alu blister pack.

Neotack[®] Injection : Box containing 2x5 ampoules in blister pack.

Neotack[®] Syrup : PET bottle containing 100ml syrup and a measuring cup.

® Registered Trade Mark

Manufactured by



**SQUARE
PHARMACEUTICALS LTD.
BANGLADESH**